Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1813 1
1842 1
1888 1
1919 1
1929 1
1947 1
1949 1
1950 1
1951 2
1952 2
1956 1
1957 4
1958 3
1959 4
1960 1
1962 2
1963 5
1964 3
1965 5
1966 6
1967 11
1968 5
1969 22
1970 11
1971 10
1972 9
1973 15
1974 17
1975 12
1976 34
1977 27
1978 24
1979 28
1980 32
1981 26
1982 40
1983 43
1984 34
1985 38
1986 42
1987 43
1988 59
1989 66
1990 53
1991 74
1992 77
1993 62
1994 68
1995 68
1996 71
1997 80
1998 80
1999 76
2000 85
2001 90
2002 86
2003 91
2004 84
2005 123
2006 113
2007 120
2008 143
2009 122
2010 141
2011 142
2012 143
2013 163
2014 172
2015 214
2016 193
2017 192
2018 180
2019 166
2020 211
2021 245
2022 213
2023 230
2024 202

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,860 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.
Meduri GU, Shih MC, Bridges L, Martin TJ, El-Solh A, Seam N, Davis-Karim A, Umberger R, Anzueto A, Sriram P, Lan C, Restrepo MI, Guardiola JJ, Buck T, Johnson DP, Suffredini A, Bell WA, Lin J, Zhao L, Uyeda L, Nielsen L, Huang GD; ESCAPe Study Group. Meduri GU, et al. Intensive Care Med. 2022 Aug;48(8):1009-1023. doi: 10.1007/s00134-022-06684-3. Epub 2022 May 13. Intensive Care Med. 2022. PMID: 35723686 Free PMC article. Clinical Trial.
Horner Syndrome: A Clinical Review.
Martin TJ. Martin TJ. ACS Chem Neurosci. 2018 Feb 21;9(2):177-186. doi: 10.1021/acschemneuro.7b00405. Epub 2017 Dec 20. ACS Chem Neurosci. 2018. PMID: 29260849 Review.
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, McCarthy PL, Munshi NC. Raje NS, et al. Lancet Haematol. 2022 Feb;9(2):e143-e161. doi: 10.1016/S2352-3026(21)00283-0. Lancet Haematol. 2022. PMID: 35114152 Review.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Facon T, et al. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3. N Engl J Med. 2024. PMID: 38832972 Clinical Trial.
Discovery of a first-in-class EZH2 selective degrader.
Ma A, Stratikopoulos E, Park KS, Wei J, Martin TC, Yang X, Schwarz M, Leshchenko V, Rialdi A, Dale B, Lagana A, Guccione E, Parekh S, Parsons R, Jin J. Ma A, et al. Nat Chem Biol. 2020 Feb;16(2):214-222. doi: 10.1038/s41589-019-0421-4. Epub 2019 Dec 9. Nat Chem Biol. 2020. PMID: 31819273 Free PMC article.
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.
4,860 results